Yield10 Bioscience Announces Second Quarter 2020 Financial Results
August 11, 2020 16:05 ET
|
Yield10 Bioscience, Inc.
WOBURN, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today reported financial results for the three and six months ended June...
LogicBio Therapeutics Announces SUNRISE Phase 1/2 Clinical Design for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients
August 10, 2020 06:35 ET
|
LogicBio Therapeutics
– LogicBio’s First IND Clearance Leveraging GeneRide, an In Vivo Homologous Recombination-based Genome Editing Platform – – Enrollment to Start with Patients as Young as 3 Years Old, De-escalating...
LogicBio Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates
August 10, 2020 06:30 ET
|
LogicBio Therapeutics
LEXINGTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a company dedicated to extending the reach of genetic medicine with...
LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones
January 10, 2020 07:05 ET
|
LogicBio Therapeutics
– Filed IND for lead GeneRide™ candidate LB-001 in pediatric MMA patients –– Phase 1/2 trial initiation planned for H1 2020, with preliminary data in H2 2020 –– Established research collaboration with...
LogicBio Therapeutics Announces Collaboration with Takeda to Develop New Genome Editing Candidate LB-301 for the Treatment of Crigler-Najjar Syndrome
January 10, 2020 07:00 ET
|
LogicBio Therapeutics
– LB-301 is a recombinant AAV vector with a UGT1A1 gene leveraging GeneRide™ genome editing platform for the treatment of Crigler-Najjar syndrome – – The collaboration agreement grants Takeda an...
LogicBio Therapeutics Extends Sponsored Research Agreement with Oregon Health & Science University to Explore Translation of Pharmaceutically-Driven Selective Advantage for Future GeneRide™ Candidates
December 17, 2019 08:00 ET
|
LogicBio Therapeutics
CAMBRIDGE, Mass., Dec. 17, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric...
Precision BioSciences Reports Third Quarter 2019 Financial Results and Highlights Ongoing Operational Progress Including Initial Data from PBCAR0191 Phase 1/2a Clinical Trial
November 12, 2019 07:15 ET
|
Precision Biosciences
DURHAM, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its...
Yield10 Bioscience Signs Exclusive Worldwide License with University of Missouri for Advanced Technology Used to Boost Oil Content in Crops
May 08, 2019 08:30 ET
|
Yield10 Bioscience, Inc.
WOBURN, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company which uses its “Trait Factory” to develop high value seed traits for the...
Yield10 Bioscience CEO Oliver Peoples to Present at the Advanced Bioeconomy Leadership Conference on April 3, 2019
April 02, 2019 08:00 ET
|
Yield10 Bioscience, Inc.
WOBURN, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company which uses its “Trait Factory” to develop high value seed traits for the...
Yield10 Bioscience Obtains Nonregulated Status for its Novel CRISPR-Cas9 Triple Gene Edited Camelina Plant Lines to Boost Seed Oil Content
October 02, 2018 08:00 ET
|
Yield10 Bioscience, Inc.
--USDA-APHIS Response Marks Clearance of Yield10’s First Triple Genome-edited Plant Lines --Favorable Response Accelerates Path to U.S. Field Trials in 2019 WOBURN, Mass., Oct. 02, 2018 (GLOBE...